Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.
Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.
Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.
Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.